About: Can COVID 2019 disease induces a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Can COVID 2019 disease induces a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases? Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Can COVID 2019 disease induces a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?
Creator	Mansueto, Gelsomina Napoli, Claudio Niola, Massimo
Source	Elsevier; Medline; PMC; WHO
abstract	A novel coronavirus SARS-CoV-2 causes acute respiratory distress syndrome (ARDS) with cardiovascular and multiple organ failure till death. The main mechanisms of virus internalization and interaction with the host are down-regulation or upregulation of the ACE2 receptor, the surface glycoprotein competition mechanism for the binding of porphyrin to iron in heme formation as well as interference with the immune system. The interference on renin–angiotensin–aldosterone system (RAAS) activation, heme formation, and the immune response is responsible for infection diffusion, endothelial dysfunction, vasoconstriction, oxidative damage and releasing of inflammatory mediators. The main pathological findings are bilateral interstitial pneumonia with diffuse alveolar damage (DAD). Because ACE receptor is also present in the endothelium of other districts as well as in different cell types, and as porphyrins are transporters in the blood and other biological liquids of iron forming heme, which is important in the assembly of the hemoglobin, myoglobin and the cytochromes, multiorgan damage occurs both primitive and secondary to lung damage. More relevantly, myocarditis, acute myocardial infarction, thromboembolism, and disseminated intravasal coagulation (DIC) are described as complications in patients with poor outcome. Here, we investigated the role of SARSCoV-2 on the cardiovascular system and in patients with cardiovascular comorbidities, and possible drug interference on the heart.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.1016/j.prp.2020.153086
bibo:pmid	32825954
has license	no-cc
sha1sum (hex)	d9a250e71464fd6d580fd68d143402131e47ae6e
schema:url	https://doi.org/10.1016/j.prp.2020.153086
resource representing a document's title	Can COVID 2019 disease induces a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?
has PubMed Central identifier	PMC7319650
has PubMed identifier	32825954
schema:publication	Pathol Res Pract
resource representing a document's body	covid:d9a250e71464fd6d580fd68d143402131e47ae6e#body_text
is schema:about of	named entity 'comorbidities' named entity 'infarction' named entity 'disease' named entity 'induces' named entity 'specific' named entity 'N A' named entity 'multiple organ failure' named entity 'DIC' named entity 'disseminated intravascular coagulation' named entity 'cardiovascular diseases' named entity 'arrhythmias' named entity 'acute respiratory distress syndrome' named entity 'Myocarditis' named entity 'cardiovascular diseases' named entity 'cardiovascular' named entity 'ACE2' named entity 'dyspnoea' named entity 'lung disease' named entity 'SARS-CoV-2' named entity 'ventricular bigeminy' named entity 'COVID' named entity 'COVID' named entity 'thromboembolism' named entity 'endothelial' named entity 'active site' named entity 'Covid' named entity 'cardiomyocytes' named entity 'adverse event' named entity 'SARS-CoV-2' named entity 'cardiovascular complications' named entity 'Avigan' named entity 'ACE2 receptor' named entity 'autopsy' named entity 'WHO' named entity 'RAAS' named entity 'antihypertensive' named entity 'China' named entity 'myocardial infarction' named entity 'Italian' named entity 'cytoplasm' named entity 'metabolic pathway' named entity 'autoimmune responses' named entity 'DIC' named entity 'cardiovascular diseases' named entity 'ACE inhibitors' named entity 'diabetes' named entity 'necrosis' named entity 'differential diagnosis' named entity 'atrioventricular block' named entity 'CoV-19' named entity 'sudden death' named entity 'myocardial infarction' named entity 'IL-6' named entity 'diabetes' named entity 'antigenic peptides' named entity 'SARS-CoV-2' named entity 'hypoxic' named entity 'hyperplasia' named entity 'hypertension' named entity 'cell types' named entity 'statins' named entity 'hypercoagulable state' named entity 'bronchiectasis' named entity 'diabetes' named entity 'thromboembolism' named entity 'lysosomal' named entity 'myocarditis' named entity 'anticoagulants' named entity 'cardiovascular risk' named entity 'clinical studies' named entity 'endothelium' named entity 'enterovirus' named entity 'RNA virus' named entity 'shortness of breath' named entity 'direct action' named entity 'SARS CoV' named entity 'hypertension' named entity 'P2Y12 inhibitors' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software